← Leaderboards
Stanton Furst McHardy
University Of Texas Hlth Science Center
$2,435,808
Attributed
$5,803,773
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,803,773 · 4
By mechanism
R01$4,993,615 · 3
R56$810,158 · 1
Top collaborators
- Jose L. Lopez-Ribot5 shared
- Andrew Jacob Brenner3 shared
- William P Clarke3 shared
- Ratna K Vadlamudi3 shared
- Sevan Najm Alwan1 shared
- Michael Darin Cameron1 shared
- Philip T Loverde1 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Andrew Jacob Brenner$6,506,512
- Gangadhara R Sareddy$1,601,264
- Luiz Otavio Penalva$3,130,773
- Sevan Najm Alwan$202,540
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPropertyIn VitroPharmaceutical PreparationsDesignLeadStructure-Activity RelationshipStructureResistanceToxic EffectPharmaceutical ChemistryInnovationSeriesScreeningAdultAgonistMediatingCellsLigandsToxicologyBindingSafetyMorbidity - Disease RateChemical Property
Grant awards (12)
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$530,240
R01 · FY2025 · CA
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia$508,826
R01 · FY2025 · DA
Preclinical Testing of Potential Next-generation Antischistosomal Compounds$810,158
R56 · FY2024 · AI
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia$508,286
R01 · FY2024 · DA
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$502,525
R01 · FY2024 · CA
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia$557,766
R01 · FY2023 · DA
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$548,472
R01 · FY2023 · CA
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2019 · AI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2018 · AI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2017 · AI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2016 · AI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2015 · AI